2,912 results on '"DiPersio, John F."'
Search Results
352. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes
353. Long-Term Remissions in Patients with Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia Undergoing Allogeneic Transplantation Following a Reduced Intensity Conditioning Regimen of 550 cGy Total Body Irradiation and Cyclophosphamide
354. Allogeneic Transplantation for Myelodysplastic Syndromes
355. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia
356. Clonal Architecture of Secondary Acute Myeloid Leukemia
357. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
358. 208 - Conditioning with Fully Ablative Antibody-Drug Conjugates Enables Hematopoietic Stem Cell Transplantation with Potent Antileukemia Activity
359. 210 - Streptavidin-Drug Conjugates Streamline Identification of Optimal Toxic Payloads for Antibody-Based Hematopoietic Stem Cell Transplantation Conditioning
360. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
361. A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes
362. Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury
363. Role of Hematopoietic Stem Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome
364. Diabetic Stem-Cell “Mobilopathy”
365. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study
366. Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene
367. Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
368. VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival
369. BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
370. A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma
371. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
372. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
373. Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma
374. Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data
375. Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo
376. Addressing Relapsed Disease Following Hematopoietic Stem Cell Transplantation
377. Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program
378. Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML
379. TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia
380. Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT)
381. The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo
382. Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant
383. Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
384. Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?
385. Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation
386. Targeting CXCR4 in AML and ALL
387. Immunotherapy for T-Cell ALL and T-Cell NHL
388. Abstract CT035: TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia
389. Abstract 5699: AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients
390. The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced‐intensity hematopoietic peripheral blood cell transplant – a retrospective study
391. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
392. Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post–allogeneic hematopoietic stem cell transplant patient
393. Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors permit allogeneic hematopoietic stem cell transplantation with minimal treatment-related toxicity
394. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
395. Selective targeting of α4β1 integrin attenuates murine graft versus host disease
396. Antibody-Drug Conjugates Targeting CD45 Plus Janus Kinase (JAK) Inhibitors As Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation
397. Phase 1 Clinical Study of Mgta-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF
398. TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia
399. The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation
400. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.